CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
Combination of sorafenib and everolimusdrug
Likely dose
Combination of sorafenib and everolimus 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00933777
NCT00933777Phase 1Completed
CompareCT.gov

SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors

University of Cologne·interventional·Posted Jul 7, 2009·Updated May 25, 2016

In Brief

A Phase 1 clinical trial evaluating Combination of sorafenib and everolimus for Unspecified Adult Solid Tumor, Protocol Specific and Non-Small Cell Lung Cancer. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Dose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished). Extension part:Treatment of non-small cell lung cancer (NSCLC) with KRAS mutation after ≥ 1st relapse (recruiting)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 7, 2009
Enrollment StartJul 1, 2009
Primary CompletionFeb 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 17.0 years ago

Interventions

Combination of sorafenib and everolimusdrug

Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg